Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - tapentadol (unii: h8a007m585) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - 1 indications and usage nucynta® (tapentadol) is indicated for the relief of moderate to severe acute pain in patients 18 years of age or older. 4 contraindications 4.1 impaired pulmonary function like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . 4.2 paralytic ileus like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. 4.3 monoamine oxidase inhibitors nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which ma

Canada - English - Health Canada

apotex inc - tapentadol (tapentadol hydrochloride) - tablet (immediate release) - 50mg - tapentadol (tapentadol hydrochloride) 50mg

Canada - English - Health Canada

apotex inc - tapentadol (tapentadol hydrochloride) - tablet (immediate release) - 75mg - tapentadol (tapentadol hydrochloride) 75mg

Canada - English - Health Canada

apotex inc - tapentadol (tapentadol hydrochloride) - tablet (immediate release) - 100mg - tapentadol (tapentadol hydrochloride) 100mg